Skip to main content
Midas Edge

ARTELO BIOSCIENCES INC

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

ARTL$2.14+3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a)Financial Statements
(1)Financial statements for our company are listed in the index under Item 8 of this document.
(2)All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

(b) Exhibits

ExhibitNumberDescriptionFormFile No.FilingDateFiledHerewith
3.1Articles of Incorporation, as amended10-Q001-389515/11/2023
3.2Amended and Restated Bylaws8-K001-3895104/21/2023
4.1Description of Securities*
4.2Specimen Common Stock CertificateS-8333-25138712/16/2020
10.1Purchase Agreement between the Company and Lincoln Park Capital Fund, LLC, dated May 13, 2022.8-K001-3895105/16/2022
10.2Registration Rights Agreement between the Company and Lincoln Park Capital Fund, LLC, dated May 13, 2022.8-K001-3895105/16/2022
10.3#Amended and Restated Employment Agreement by and between the Company and Gregory D. Gorgas dated August 30, 2019.10-K001-3895111/25/2019
10.4Securities Purchase Agreement by and between the Company and Gregory D. Gorgas dated April 3, 2017.8-K333-1992134/7/2017
10.5#Form of Indemnification Agreement8-K333-1992135/8/2017
10.6Stock Purchase Agreement dated May 4, 20178-K333-1992135/8/2017
10.7Form of Private Placement Subscription Agreement8-K333-1992138/4/2017
10.8Form of Registration Rights Agreement8-K333-1992138/4/2017
10.9Stock Purchase Agreement dated as of August 1, 20178-K333-1992138/4/2017
10.10Material and Data Transfer, Option and License Agreement dated as of December 20, 2017 by and between the Company and NEOMED Institute+10-Q333-1992131/16/2018
10.11+First Amendment to Material and Data Transfer, Option and License Agreement by and between the Company and NEOMED Institute, dated as of January 4, 201910-Q333-1992134/15/2019
10.12#2018 Equity Incentive Plan and Forms of Award Agreement Thereunder8-K001-3895112/3/2020
10.13+License Agreement with Stony Brook University, by and between the Company and Stony Brook University, dated January 18, 2018S-1/A333-2227564/17/2018
21.1List of subsidiaries10-Q001-3895111/08/2023
23.1Consent Of Independent Registered Public Accounting Firm*
31.1Section 302 Certification*
32.1 **Section 906 Certification*
97.1Compensation Recovery Policy*
101 INSInline XBRL Instance Document
101 SCHInline XBRL Taxonomy Extension Schema Document
101 CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101 DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101 LABInline XBRL Taxonomy Extension Label Linkbase Document
101 PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover page Interactive Data File (embedded with the Inline XBRL document)
#Management contracts or compensatory plans, contracts or arrangements.
+Certain portions of this exhibit have been omitted.
**The certification attached as Exhibit 32.1 that accompanies this Annual Report, is deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Artelo Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.